Cetuximab improves locoregional control and survival of locoregionally advanced head and neck cancer: Independent review of mature data with a median follow-up of 45 months. Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Bonner, JA
  • Harari, PM
  • Giralt, J
  • Azarnia, N
  • Cohen, RB
  • Jones, C
  • Sur, Ranjan
  • Raben, D
  • Baselga, J
  • Spencer, S
  • Amellal, N
  • Rowinsky, E
  • Ang, KK

publication date

  • December 15, 2005